Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Targeted Search
Clinical Trials Search Results
Query: "AREA[SponsorSearch](Astex Pharmaceuticals, Inc.)"
Count: 93
Selected: 0
| NCT ID | Title |
|---|
| NCT00042003 | Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec) | ||
| NCT00041990 | Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Accelerated Phase Who Are Refractory to Imatinib Mesylate (Gleevec) | ||
| NCT05403450 | A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL) | ||
| NCT04953923 | Thorough QT Assessment of Cedazuridine in Healthy Subjects | ||
| NCT04953910 | Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment | ||
| NCT04953897 | Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment | ||
| NCT04657081 | Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML) | ||
| NCT04637009 | A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms | ||
| NCT04479800 | Effect of Food on the Pharmacokinetics of ASTX660 in Healthy Volunteers | ||
| NCT04466514 | A Phase 1 Study to Evaluate the Effect of Food on Pharmacokinetics of ASTX029 | ||
| NCT04411030 | A Study to Investigate the Effect of CYP3A4 Inhibition on the Single Dose Pharmacokinetics of ASTX660 and the Effect of a Single Dose of ASTX660 on the Pharmacokinetics of the CYP3A4 Substrate Midazolam | ||
| NCT04282668 | A Study of TAS1440 With ATRA in Subjects With r/r AML | ||
| NCT04256317 | A Study of ASTX030 (Cedazuridine in Combination With Azacitidine) in MDS, CMML, or AML | ||
| NCT04155580 | A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) | ||
| NCT04093570 | A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers | ||
| NCT03975387 | Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53 | ||
| NCT03813186 | Effect of Food on Blood Levels of ASTX727 | ||
| NCT03603964 | Guadecitabine Extension Study | ||
| NCT03520075 | Study of ASTX029 in Subjects With Advanced Solid Tumors | ||
| NCT03502668 | Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS | ||
| NCT03306264 | Study of ASTX727 vs IV Decitabine in MDS, CMML, and AML | ||
| NCT02920008 | Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia | ||
| NCT02907359 | Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs | ||
| NCT02503423 | Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas | ||
| NCT02348489 | SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction | ||
| NCT02103478 | Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS) | ||
| NCT01752933 | SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) | ||
| NCT01712217 | A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib | ||
| NCT01696032 | SGI-110 in Combination With Carboplatin in Ovarian Cancer | ||
| NCT01685268 | A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate | ||
| NCT01357395 | A Phase 2, Open-Label Study of Amuvatinib in Combination With Platinum-Etoposide Chemotherapy in Small Cell Lung Cancer | ||
| NCT01294202 | A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST | ||
| NCT01261312 | SGI-110 in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) | ||
| NCT01239108 | Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Relapsed/Refractory Leukemias | ||
| NCT01183949 | Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma | ||
| NCT00894894 | Safety Study to Determine the Maximum Tolerated Dose, Pharmacokinetics and Pharmacodynamics of Oral MP470, a Multitargeted Tyrosine Kinase Inhibitor, in Patients With Solid Malignancies | ||
| NCT00881166 | Safety of MP470 in Combination With Standard-of-Care Chemotherapy Regimens to Treat Solid Tumors | ||
| NCT00878423 | Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors | ||
| NCT00848601 | Safety of SGI-1776, A PIM Kinase Inhibitor in Refractory Prostate Cancer and Relapsed/Refractory Non Hodgkin's Lymphoma | ||
| NCT00522990 | Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias | ||
| NCT00113256 | Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer | ||
| NCT00113113 | Study of Rubitecan in Cancer Patients With Renal or Hepatic Dysfunction | ||
| NCT00043381 | Decitabine Versus Supportive Care in Adults With Advanced-stage MDS | ||
| NCT00042016 | Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Chronic Phase Who Are Refractory to Imatinib Mesylate (Gleevec) | ||
| NCT00032773 | Dose-finding Study Using Pentostatin for Injection in the Treatment of Steroid-refractory aGvHD | ||
| NCT00504205 | MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma | ||
| NCT00005877 | Nitrocamptothecin in Treating Patients With Advanced or Recurrent Colorectal Cancer | ||
| NCT00005876 | Nitrocamptothecin in Treating Patients With Locally Advanced or Metastatic Stomach Cancer That Cannot Be Removed During Surgery | ||
| NCT00005875 | Nitrocamptothecin in Treating Patients With Metastatic Melanoma | ||
| NCT00005874 | Nitrocamptothecin in Treating Patients With Soft Tissue Sarcomas |
